Curevo Presents Positive Shingles Vaccine Outcomes Data
October 31, 2024 02:00 ET
|
Curevo Vaccine
Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine
Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week
October 16, 2024 11:00 ET
|
Curevo Vaccine
Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust immune responses with better tolerability.
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer
April 08, 2024 10:00 ET
|
Curevo Vaccine
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...
Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix
January 07, 2024 11:00 ET
|
Curevo Vaccine
-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023 08:00 ET
|
Curevo Vaccine
SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer
April 11, 2023 07:30 ET
|
Curevo Vaccine
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...